RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes
#2PRI RANKED
Most Cited Paper
in Neonatal Respiratory Health Research
18 Months Post-Publication
Class of 2026
“RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026/
Topics
Respiratory syncytial virus (RSV) · RSV prefusion F protein · RSVPreF3-Mat · Maternal immunization · RSV lower respiratory tract disease · Preterm birth · Neonatal mortality · Vaccine effectiveness · gestational age 24-34 weeks · infant protection · Randomized controlled trial · safety signal · Severe RSV disease
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Neonatal Respiratory Health Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026. Accessed 2026-07-22. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459